Rani Therapeutics (RANI) Expected to Post Earnings on Thursday

Key Points

• Rani Therapeutics is expected to report Q3 2026 results before markets open Thursday, with analysts forecasting a loss of $0.05 per share and revenue of $1.28 million.
• In its prior quarter, the company beat estimates, reporting a $0.04-per-share loss versus expectations of $0.05 and revenue of $1.71 million versus $0.93 million expected.
• Analyst sentiment is mixed but leans positive: four analysts rate the stock a Buy and one rates it a Sell, producing a “Moderate Buy” consensus and an average price target of $8.33, compared with shares recently trading near $0.62.

Rani Therapeutics (NASDAQ:RANI - Get Free Report) is anticipated to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Rani Therapeutics to announce earnings of ($0.05) per share and revenue of $1.28 million for the quarter. Investors are encouraged to explore the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Rani Therapeutics (NASDAQ:RANI - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.01. The business had revenue of $1.71 million for the quarter, compared to analyst estimates of $0.93 million. On average, analysts expect Rani Therapeutics to post ($0.17) EPS for the current fiscal year and ($0.20) EPS for the next fiscal year.

Rani Therapeutics Trading Up 1.0%

Shares of NASDAQ RANI opened at $0.62 on Thursday. Rani Therapeutics has a 1 year low of $0.57 and a 1 year high of $2.63. The firm's 50-day moving average is $0.78 and its 200-day moving average is $0.95. The firm has a market capitalization of $85.77 million, a PE ratio of -2.28 and a beta of 0.69.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on RANI. Chardan Capital restated a "buy" rating on shares of Rani Therapeutics in a report on Thursday, October 22nd. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Rani Therapeutics in a report on Thursday, October 15th. Finally, HC Wainwright reiterated a "buy" rating on shares of Rani Therapeutics in a research report on Tuesday, October 6th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $8.33.

Rani Therapeutics Company Profile

Rani Therapeutics Holdings, Inc is a clinical-stage biotherapeutics company developing technology designed to deliver biologic medicines orally. Its proprietary RaniPill platform is an ingestible robotic capsule intended to transport biologic drugs through the stomach and release them into the small intestine, where they can be absorbed into the bloodstream. The approach is intended to address the limitations of many biologic therapies, which are commonly administered by injection or infusion.

The company is advancing the RaniPill platform for potential use with a range of large-molecule medicines, including peptides, proteins and antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.